CBIO Crescent Biopharma, Inc.
$19.41▼ -0.26%
Healthcare
Other
After hours
$19.41▲ +0.00%
Sep 11, 7:30 PM ET
Volume 264.4K
Avg Volume (10D) 358.1K
Key Metrics & Fundamentals
Market Cap
$721.02M
P/E Ratio
–
Div Yield
–%
52W Range
8.72 - 27.41
% vs 50 MA
14.51%
% vs 200 MA
24.47%
RSI-14
58.0
MACD Histogram
+0.1800
Beta (1Y vs SPY)
0.87
Free Cash Flow
-$19.48M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$24.77M
COGS
–
Operating Exp
$26.36M
Operating Income
-$26.36M
EBIT
-$26.36M
Pretax Income
-$24.84M
Net Income
-$24.84M
EPS (Diluted)
-0.74
Price & Volume History
Loading chart…
Recent News
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Investor's Business Daily · Sep 3, 2026 8:51 PM
Crescent Biopharma to Present at September Investor Conferences
GlobeNewswire · Sep 3, 2026 11:30 AM
Crescent Biopharma Announces Grants of Inducement Awards
GlobeNewswire · Aug 3, 2026 11:30 AM
Crescent Biopharma: Q2 Earnings Snapshot
Associated Press · Jul 30, 2026 11:43 AM
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · Jul 30, 2026 11:35 AM
Crescent Biopharma Announces Grants of Inducement Awards
GlobeNewswire · Jul 23, 2026 8:15 PM
Crescent Biopharma Closes $143.7 Million Public Offering
MT Newswires · Jul 16, 2026 8:22 PM
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire · Jul 16, 2026 8:01 PM
Crescent Biopharma Prices $125 Million Common, Warrant Offering
MT Newswires · Jul 15, 2026 7:52 AM
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewswire · Jul 15, 2026 1:45 AM
Financial Overview - Income Statement
Quarterly
Mar 2026
See CBIO's money flow as a full page
Social Sentiment
No Reddit posts found for CBIO.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.